Development of cancer prognostic signature based on pan-cancer proteomics

References

• Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Cortes J, Perez-Garcia JM, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70:105–124.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang G, Zhang L, et al. Comprehensive review of web servers and bioinformatics tools for cancer prognosis analysis. Front Oncol. 2020;10:68.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.
   PubMedGoogle Scholar
• Bradshaw RA, Hondermarck H, Rodriguez H. Cancer proteomics and the elusive diagnostic biomarkers. Proteomics. 2019;19:e1800445.
   PubMed Web of Science ®Google Scholar
• Quesada-Calvo F, Massot C, Bertrand V, et al. OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clin Proteomics. 2017;14:9.
   PubMed Web of Science ®Google Scholar
• Burns J, Wilding CP. Proteomic research in sarcomas - current status and future opportunities. Semin Cancer Biol. 2020;61:56–70.
   PubMed Web of Science ®Google Scholar
• Noujaim J, Payne LS, Judson I, et al. Phosphoproteomics in translational research: a sarcoma perspective. Ann Oncol. 2016;27:787–794.
   PubMed Web of Science ®Google Scholar
• Fumet JD, Truntzer C, Yarchoan M, et al. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40–50.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang L, Qu Y. Targeting the beta-catenin signaling for cancer therapy. Pharmacol Res. 2020;160:104794.
   PubMed Web of Science ®Google Scholar
• Zhao H, Mu X, Zhang X, et al. Lung cancer inhibition by betulinic acid nanoparticles via adenosine 5ʹ-Triphosphate (ATP)-binding cassette transporter G1 gene downregulation. Med Sci Monit. 2020;26:e922092.
   PubMed Web of Science ®Google Scholar
• Wu P, Heins ZJ, Muller JT, et al. Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal. Mol Cell Proteomics. 2019;18:1893–1898.
   PubMed Web of Science ®Google Scholar
• Chen B, Hua Z, Qin X, et al. Integrated microarray to identify the Hub miRNAs and constructed miRNA-mRNA network in neuroblastoma via bioinformatics analysis. Neurochem Res. 2020.
   Web of Science ®Google Scholar
• Kim SM, Kim Y, Jeong K, et al. Logistic LASSO regression for the diagnosis of breast cancer using clinical demographic data and the BI-RADS lexicon for ultrasonography. Ultrasonography. 2018;37:36–42.
   PubMed Web of Science ®Google Scholar
• Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811–815.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166.
   PubMed Web of Science ®Google Scholar
• Ito Y, Takeda T, Sakon M, et al. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology. 2000;59:68–74.
   PubMed Web of Science ®Google Scholar
• Hongo F, Takaha N, Oishi M, et al. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. Urol Oncol. 2014;32:1240–1246.
   PubMed Web of Science ®Google Scholar
• Braun KA, Breeden LL. Nascent transcription of MCM2-7 is important for nuclear localization of the minichromosome maintenance complex in G1. Mol Biol Cell. 2007;18:1447–1456.
   PubMed Web of Science ®Google Scholar
• Chen G, Luo Y, Warncke K, et al. Acetylation regulates ribonucleotide reductase activity and cancer cell growth. Nat Commun. 2019;10:3213.
   PubMed Web of Science ®Google Scholar
• Nesterova M, Bossis I, Wen F, et al. An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits. J Clin Endocrinol Metab. 2008;93:565–571.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–1664.
   PubMed Web of Science ®Google Scholar
• Veeranki OL, Tong Z, Mejia A, et al. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019;12:12.
   Web of Science ®Google Scholar
• Asberg C, Hjalmarson O, Alm J, et al. Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis. J Inherit Metab Dis. 2010;33 Suppl 3:S113–21.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu Q, Qiu J. Accumulation of fructose 1,6-bisphosphate protects clear cell renal cell carcinoma from oxidative stress. Lab Invest. 2019;99:898–908.
   PubMed Web of Science ®Google Scholar
• Xie J, Ye J, Cai Z, et al. GPD1 enhances the anti-cancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate. Cancer Res. 2020;80:2150-2162.
   Web of Science ®Google Scholar
• Leithner K. Epigenetic marks repressing gluconeogenesis in liver and kidney cancer. Cancer Res. 2020;80:657–658.
   PubMed Web of Science ®Google Scholar
• Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013;45:251–262.
   PubMed Web of Science ®Google Scholar
• Milne K, Sun J, Zaal EA, et al. A fragment-like approach to PYCR1 inhibition. Bioorg Med Chem Lett. 2019;29:2626–2631.
   PubMed Web of Science ®Google Scholar
• Liu X, Han C, Liao X, et al. Genetic variants in the exon region of versican predict survival of patients with resected early-stage hepatitis B virus-associated hepatocellular carcinoma. Cancer Manag Res. 2018;10:1027–1036.
   PubMed Web of Science ®Google Scholar
• Salem M, O’Brien JA, Bernaudo S, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-Versican pathway. Cancer Res. 2018;78:4175–4190.
   PubMed Web of Science ®Google Scholar
• Long X, Deng Z, Li G, et al. Identification of critical genes to predict recurrence and death in colon cancer: integrating gene expression and bioinformatics analysis. Cancer Cell Int. 2018;18:139.
   PubMed Web of Science ®Google Scholar
• Bornstein P, Armstrong LC, Hankenson KD, et al. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 2000;19:557–568.
   PubMed Web of Science ®Google Scholar
• Goldoni S, Humphries A, Nystrom A, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 2009;185:743–754.
   PubMed Web of Science ®Google Scholar
• Wang X. Role of clinical bioinformatics in the development of network-based Biomarkers. J Clin Bioinforma. 2011;1:28.
   PubMedGoogle Scholar
• Gov E, Arga KY. Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer. Sci Rep. 2017;7:4996.
   PubMedGoogle Scholar
• Dos Santos P, Machado ART, De Grandis RA, et al. Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020;136:111047.
   PubMed Web of Science ®Google Scholar
• Sun Y, Long H, Sun L, et al. PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients. Cancer Cell Int. 2019;19:253.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu T, Hu L, et al. Identification and characterization of the promoter of cancer-related gene LOXL2. Exp Cell Res. 2020;387:111786.
   PubMed Web of Science ®Google Scholar
• Liu CN, Zhang HY, Liu CL, et al. Upregulation of lncRNA CALML3-AS1 promotes cell proliferation and metastasis in cervical cancer via activation of the Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23:5611–5620.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Behring M, Kim HG, et al. Targeting P4HA1 with a small molecule inhibitor in a colorectal cancer PDX model. Transl Oncol. 2020;13:100754.
   PubMed Web of Science ®Google Scholar
• Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39:2040–2054.
   PubMed Web of Science ®Google Scholar
• Xu L, Zheng Y, Wang J, et al. IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice. Biotechnol Lett. 2020;42:1113-1121.
   Web of Science ®Google Scholar
• Chukkapalli S, Amessou M, Dekhil H, et al. Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis. 2014;35:877–885.
   PubMed Web of Science ®Google Scholar
• Milanese JS, Tibiche C, Zou J, et al. Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients. NPJ Precis Oncol. 2019;3:28.
   PubMed Web of Science ®Google Scholar
• Xu X, Li J, Zou J, et al. Association of germline variants in natural killer cells with tumor immune microenvironment subtypes, tumor-infiltrating lymphocytes, immunotherapy response, clinical outcomes, and cancer risk. JAMA Network Open. 2019;2:e199292.
   PubMed Web of Science ®Google Scholar
• Jiang X, Asad M, Li L, et al. Germline genomes have a dominant-heritable contribution to cancer immune evasion and immunotherapy response. Quant Biol. 2020;8:216–227.
   Google Scholar
• Long A, Dominguez D, Qin L, et al. Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J Immunol. 2018;201:3456–3464.
   PubMed Web of Science ®Google Scholar
• Iseka FM, Goetz BT, Mushtaq I, et al. Role of the EHD family of endocytic recycling regulators for TCR recycling and T cell function. J Immunol. 2018;200:483–499.
   PubMed Web of Science ®Google Scholar
• Gao S, Tibiche C, Zou J, et al. Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer. JAMA Oncol. 2016;2:37–45.
   PubMed Web of Science ®Google Scholar
• Wang E, Zaman N, McGee S, et al. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol. 2015;30:4–12.
   PubMed Web of Science ®Google Scholar